People
Who mixed things up in the biotech world this past week? Pfizer announces its leadership team, Rheos gets a new COO, and board of directors updates from multiple biopharma companies.
Owlstone Medical today announces the appointment of Dr. Richard A Yost to its Scientific Advisory Board.
Rewind Therapeutics today announces the establishment of a Scientific Advisory Board (SAB) composed of eminent scientists in the fields of multiple sclerosis, myelination and neuroscience drug discovery and development.
For those looking for work, it’s good to know that some positions are in such demand that employers are falling all over themselves to offer hiring incentives. That’s the case with the biotech sector in Massachusetts, as many companies are dangling almost unheard-of benefits as incentives.
UH Biologist Discovers Protein Partnership That Protects Blood Vessels
There is a lot of anticipated excitement for multiple sclerosis treatments unveiled by Biogen at the 34th Congress of the European Committee for Treatment and Research in MS in Berlin.
As the timeline shortens for Albert Bourla to take over the reins of Pfizer from Chief Executive Officer Ian Read, the company has released details of the new senior management team that will continue to lead the company forward.
The neuroprotection biotech also strengthens its scientific team with the arrival of Dr. Amit Bar-Or, a multiple sclerosis specialist, to the Scientific Advisory Board
Kenneth Frazier, chief executive officer of Merck, speaking with the Economic Club of New York, joined a growing list of pharmaceutical chiefs in criticizing the role of middlemen in rising drug prices.
Imugene Limited today announced the appointment of Dr Josep Tabernero, the President of the European Society for Medical Oncology, to its Scientific Advisory Board.
PRESS RELEASES